-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Biogen, Raises Price Target to $300

Benzinga·10/29/2026 16:19:42
Listen to the news
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $270 to $300.